Copley Scientific has published a new, freely available white paper that discusses ‘Refining inhaled product testing’. This timely review comes as the pharmaceutical industry maintains its drive towards greater efficiency, from faster time to market through to better manufacturing practice. It is against this backdrop that analytical tools are currently facing considerable scrutiny as to whether they provide relevant information and enable maximum productivity.
Inhaled product development is uniquely challenging but there is a desire to move towards a more knowledge-driven approach. Focusing on the core technique of cascade impaction, Mark Copley looks at how testing is being refined to support the aspiration of more efficient practice and the generation of better product understanding. A key goal is to achieve better in vitro –in vivo relationships, as well as reducing the burden of QC testing.
‘Refining inhaled product testing’ reviews current testing regimes and discusses ideas surrounding Abbreviated Impactor Measurement/Efficient Data Analysis, and the progress that has been made, summarising experimental work to date. Changes to nebulizer testing are given as an example of how some areas are already being revised, with more representative breath profiles and cooling for more accurate APSD measurement.
To download this and other white papers from Copley Scientific go to http://bit.ly/COPWP
About Copley Scientific
Copley Scientific is recognised as the world’s leading manufacturer and supplier of inhaler test equipment and is a major provider of testing systems for other pharmaceutical dosage forms. The company is also active in detergent testing, air sampling and aerosol characterisation.
Copley Scientific’s pharmaceutical product range includes test equipment for: delivered dose uniformity and aerodynamic particle size measurement of metered-dose inhalers, dry powder inhalers, nebulizers and nasal sprays; as well as tablets (dissolution, disintegration, friability and hardness) capsules, powders, suppositories and transdermals.
Copley Scientific has offices in the UK and Switzerland. The company works in partnership with aerosol particle science experts MSP Corporation in North America, and also distributes MSP Corporation’s air sampling and aerosol characterisation products throughout Europe.
Serving the pharmaceutical and associated industries, Copley Scientific offers an extensive range of equipment for research, development and quality control, as well as full validation and aftersales services. This broad range of products is supplied and supported worldwide through a network of specialist distributors. www.copleyscientific.com